Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
4BIO Capital, an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, announces today that the Development Bank of Japan (DBJ), Japan’s sovereign development bank, has entered into an investment agreement with its third fund, 4BIO Ventures III. The Group is targeting $200–300 million for the final close of the fund, expected to be in 2024. This investment by the DBJ represents the Bank’s first investment into a UK life sciences fund.
4BIO Ventures III is already deploying capital and is focused on forming and investing in private companies addressing the world’s most impactful disease areas by developing advanced therapies and other emerging technologies, including cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The Group’s objective is to create and invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. 4BIO continues to prioritise novel technologies that resolve the largest industry pain points of advanced therapies in order to enable next-generation therapeutic assets.
By connecting Japan’s unique startup ecosystem with its counterparts overseas, DBJ and its subsidiary, DBJ Capital K.K., will work alongside 4BIO Capital to support the creation of new, potentially life-transforming medical treatments for all patients around the world.
About 4BIO Capital
4BIO Capital is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future. 4BIO’s objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.
This article is part of our Tokyo FinTech Publication, please follow us to read more from our writers, like hundreds of readers do every day. Please also register for our short weekly digest, the “Japan FinTech Observer”, on Medium or on LinkedIn.
Should you live in Tokyo, or just pass through, please also join our Tokyo FinTech Meetup. In any case, our YouTube channel and LinkedIn page are there for you as well.
